Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 ACPE Contact Hour(s) (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for neurologists, family medicine/primary care clinicians, internists, obstetricians/gynecologists/women’s health clinicians, nurses/nurse practitioners, pharmacists, physician assistants, and other members of the health care team who treat and manage patients with cluster headaches.
The goal of this activity is for members of the health care team to be better able to describe sex differences in patient demographics, clinical phenotype, chronobiology, triggers, treatment, and lifestyle in a Swedish population with cluster headache, based on a survey study of patients identified from medical records from 2014 to 2020 from hospitals and neurology clinics in Sweden.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape, LLC designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number JA0007105-0000-23-050-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 02/17/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 2/17/2023
Valid for credit through: 2/17/2024, 11:59 PM EST
processing....
Cluster headache (CH) is a severely painful headache disorder characterized by unilateral, orbital head pain often accompanied by autonomic symptoms, such as lacrimation, ptosis, or restlessness. During an active bout, headache attacks lasting between 15 and 180 minutes occur up to 8 times daily. Although CH is considered male-predominant, the reported male-to-female ratio has shifted from approximately 6:1 before 1960 to 5.1-2.5:1 in 2018. This shift may result from lifestyle changes in both sexes and/or from increased CH recognition.
Women with CH have more severe symptoms and longer headache bouts than men, and they are more likely to have a chronic subtype of the disorder, new research shows.
The study, which is the largest to date involving patients with CH, adds to a growing body of work that suggests that an illness that affects mostly men may actually have a much greater effect on women.
“The main thing from this study is to show clinicians that women can suffer from [CH] too,” senior investigator Andrea Carmine Belin, PhD, associate professor of neuroscience at the Karolinska Institutet, Stockholm, Sweden, told Medscape Medical News.
The findings were published online December 21, 2022, in Neurology.[1]
Severe and Debilitating
CH is rare, but it is among the most severe and debilitating types of headache. It causes intense pain behind the eyes. The pain has been described as being worse than the pain associated with childbirth or kidney stones.[2]
In addition, attacks can occur multiple times in a day and can last up to 3 hours.
As reported by Medscape Medical News, a recent study showed that participants with CH were significantly more likely to have comorbid conditions, including mental disorders and other neurologic diseases.[3]
In the current study,1,484 Swedish individuals were recruited for inclusion into a CH biobank, of whom 874 completed a survey that collected demographic data and information about symptoms, including severity and frequency. The patients included 575 male and 299 female participants with CH.
The study participants were identified between 2014 and 2020 by requesting medical records for International Classification of Diseases, 10th Revision (ICD-10), code G44.0 for CH from all major hospitals and neurology clinics over Sweden, as well as in conjunction with CH outpatient visits to neurology clinics. Study participants were diagnosed with CH and subtype by neurologists through structured interviews and clinical examination according to criteria of the International Classification of Headache Disorders, 3rd Edition.[1]
Each study participant completed a 3-part questionnaire that included a first part on personal, demographic and medical information. A second part was designed to assess different parts of the disease, and the third included lifestyle questions. For neurology outpatients, the questionnaire was completed in relation to the visit. All data were self-reported except CH diagnosis, which was verified using ICD-10 code G44.0. All participants were genotyped for their biological sex, and it matched their self-reported sex. The age at the time of completing the survey varied slightly between male and female participants (51.3±13.9 vs 49.0±15.0; P=.028)[1]
Gender Gap Closing?
Women were significantly more likely than men to have headache bouts lasting 4 months or longer and were more likely to have attacks that followed a circadian pattern, with early-morning onset.
Women were more likely than men to experience the onset of CH before age 20 years (23.0% vs 16.2%; odds ratio [OR], 0.64; 95% CI, 0.44-0.92; P=.020). However, there was no difference overall in the average age of disease onset.[1]
Chronic CH was nearly twice as common in women as men (18.4% vs 9.4%; OR, 0.46; 95% CI, 0.32-0.70; P=.0002). Women were also more likely to have a co-occurring migraine or tension-type headache and to have an immediate family member who had a history of CH (15.4% vs 7.1%; OR, 0.42; 95% CI, 0.27-0.66; P=.0002).[1]
CH triggered by sleep deprivation, stress, and changes in weather or temperature was also more common in women, whereas among men, attacks were more often triggered by alcohol consumption (56.5% vs 40.5%; OR, 1.91; 95% CI, 1.29-2.81; P=.001).Alcohol was the most common trigger by far (50.7%) for both men and women, and stress was the second most common trigger (26.7%), with more females being affected than males (20.5% vs 37.4%; OR, 0.43; 95% CI, 0.28-0.66; P=.0001). Most of the participants described food items or nonalcoholic beverages that may trigger an attack were chocolate, sweets or food/beverages with high sugar content, coffee/tea, (strong) cheese, food with high salt content, and spicy/pungent food.[1]
Women were more apt to use oxygen 36.5% vs 27.8%; OR, 0.67; 95% CI, 0.49-0.92; P=.013) for acute attacks and to use preventive medications. They also reported a higher incidence of ptosis (drooping eyelids; 60.5% vs 47.0%; OR, 0.58; 95% CI, 0.43-0.76; P=.0002) and restlessness (53.9 % vs 45.6%; OR, 0.72; 95% CI, 0.54-0.95; P=.024). Menstruation and other hormone-related factors were reported as triggers by 1.2% of women.[1]
Although CH remains more common in men than women, that gender gap is closing, Dr Belin said. That is in part because of better diagnosis, but also a result of a growing incidence of the disorder in women. Overall, the true number of female patients with CH is probably larger than reported, she added.
“I have patients in our cohort and our clinic who say they go to neurologists with all the symptoms of cluster headache, and the neurologists say that ‘you can’t have cluster headache because you’re a woman,’ “Dr Belin said.
The investigators have created a CH biobank and have DNA samples and clinical data on more than 900 patients with CH. That will make it easier to investigate the underlying cause of the disorder and the reasons for the differences in clinical presentation, they note.
“We’re very interested in learning more about the treatment response in men and women and why chronic cluster headache seems to be more common in women,” Dr Belin said.
Greater Awareness
In an accompanying editorial, Mark Burish, MD, PhD, from UT Health, Houston, Texas, and Richard Lipton, MD, from Albert Einstein College of Medicine, New York City, note that this is one of the most comprehensive CH studies to date.[4]
The investigators “confirm previous epidemiologic suspicions, provide new insights, and raise important questions into sex hormones and the influence of genetic factors,” Dr Burish and Dr Lipton write.
“This large study of rigorously diagnosed cluster headache patients mandates an elevated index of suspicion for cluster headache in women, and an awareness of possibly more burdensome disease in women,” the editorialists add.
The study was funded by the Swedish Brain Foundation, the Mellby Gård Foundation, the Swedish Research Council, Region Stockholm, and Karolinska Institutet Research Funds. Dr Belin has disclosed no relevant financial relationships. Dr Burish is an unpaid member of the medical advisory board of Clusterbusters. Dr Lipton serves in unpaid positions on the editorial board of Neurology and Cephalalgia and as senior advisor to Headache. Full disclosures are included in the original articles.
Neurology. Published online December 21, 2022.